Cargando…
Effects of socioeconomic status on excess mortality in patients with multiple sclerosis in France: A retrospective observational cohort study
BACKGROUND: The effects of socio-economic status on mortality in patients with multiple sclerosis is not well known. The objective was to examine mortality due to multiple sclerosis according to socio-economic status. METHODS: A retrospective observational cohort design was used with recruitment fro...
Autores principales: | Wilson, Sarah, Calocer, Floriane, Rollot, Fabien, Fauvernier, Mathieu, Remontet, Laurent, Tron, Laure, Vukusic, Sandra, Le Page, Emmanuelle, Debouverie, Marc, Ciron, Jonathan, Ruet, Aurélie, De Sèze, Jérôme, Zephir, Hélène, Moreau, Thibault, Lebrun-Frénay, Christine, Laplaud, David-Axel, Clavelou, Pierre, Labauge, Pierre, Berger, Eric, Pelletier, Jean, Heinzlef, Olivier, Thouvenot, Eric, Camdessanché, Jean Philippe, Leray, Emmanuelle, Dejardin, Olivier, Defer, Gilles |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9678948/ https://www.ncbi.nlm.nih.gov/pubmed/36426377 http://dx.doi.org/10.1016/j.lanepe.2022.100542 |
Ejemplares similares
-
Excess Mortality in Patients with Multiple Sclerosis Starts at 20 Years from Clinical Onset: Data from a Large-Scale French Observational Study
por: Leray, Emmanuelle, et al.
Publicado: (2015) -
Disability progression in multiple sclerosis patients using early first‐line treatments
por: Lefort, Mathilde, et al.
Publicado: (2022) -
MD1003 (High-Dose Pharmaceutical-Grade Biotin) for the Treatment of Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Study
por: Tourbah, Ayman, et al.
Publicado: (2018) -
MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study
por: Tourbah, Ayman, et al.
Publicado: (2016) -
Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis
por: Laplaud, David-Axel, et al.
Publicado: (2019)